Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31114914 | 1.00 | HSD17B10 (0.40) | HSD17B10CHRM2CHRM1CHRM3HPGD | |
| SCHEMBL19951601 | 1.00 | HSD17B10 (0.40) | HSD17B10CHRM2CHRM1CHRM3HPGD | |
| SCHEMBL398772 | 0.90 | HSD17B10 (0.48) | HSD17B10HPGDATMSMN1; SMN2ALDH1A1 | |
| SCHEMBL29739 | 0.90 | HSD17B10 (0.48) | HSD17B10HPGDATMSMN1; SMN2ALDH1A1 | |
| SCHEMBL539034 | 0.90 | HSD17B10 (0.48) | HSD17B10HPGDATMSMN1; SMN2ALDH1A1 | |
| SCHEMBL190190 | 0.89 | PDE8B (0.47) | HSD17B10HPGDATMSMN1; SMN2CTSK | |
| SCHEMBL24121385 | 0.84 | ATM (0.42) | HSD17B10CHRM2CHRM1CHRM3HPGD | |
| SCHEMBL4967116 | 0.84 | HSD17B10 (0.41) | HSD17B10CHRM2CHRM1CHRM3HPGD | |
| SCHEMBL8073389 | 0.84 | HSD17B10 (0.41) | HSD17B10CHRM2CHRM1CHRM3HPGD | |
| SCHEMBL71904 | 0.84 | NR1H2 (0.45) | HSD17B10CHRM2CHRM1CHRM3HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12384778-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2025-08-12 | — | — | US | disclosed |
| US-20240287059-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2024-08-29 | — | — | US | disclosed |
| CN-117157279-A | Preparation method of bicyclo compound and application of bicyclo compound as antibacterial agent | 上海济煜医药科技有限公司 | 2023-12-01 | — | — | CN | disclosed |
| US-20230338341-A1 | SUBSTITUTED 1H-IMIDAZO[4,5-b]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-26 | — | — | US | disclosed |
| US-11795166-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2023-10-24 | — | — | US | disclosed |
| US-11759455-B2 | Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GLUN2B receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-09-19 | — | — | US | disclosed |
| EP-3523311-B1 | SUBSTITUTED 1H-IMIDAZO[4,5-B]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-07 | — | — | EP | disclosed |
| CN-115819417-A | Pyrazolopyridine derivatives as HPK1 modulators and their use for the treatment of cancer | 因赛特公司 | 2023-03-21 | — | — | CN | disclosed |
| EP-4119558-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | Incyte Corporation (US) | 2023-01-18 | — | — | EP | disclosed |
| US-20230000833-A1 | SUBSTITUTED 1H-IMIDAZO[4,5-b]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-01-05 | — | — | US | disclosed |
| US-10617676-B2 | Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GluN2B receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-14 | — | — | US | disclosed |
| US-20200087301-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2020-03-19 | — | — | US | disclosed |
| WO-2020030925-A1 | HETEROCYCLIC SUBSTITUTED UREAS, FOR USE AGAINST CANCER | ARTIOS PHARMA LIMITED (GB) | 2020-02-13 | — | — | WO | disclosed |
| US-10435405-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2019-10-08 | — | — | US | disclosed |
| EP-3523311-A1 | SUBSTITUTED 1H-IMIDAZO[4,5-B]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | Janssen Pharmaceutica NV (BE) | 2019-08-14 | — | — | EP | disclosed |
| US-10266530-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2019-04-23 | — | — | US | disclosed |
| US-20190106419-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2019-04-11 | — | — | US | disclosed |
| US-20180125826-A1 | SUBSTITUTED 1H-IMIDAZO[4,5-b]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (JP) | 2018-05-10 | — | — | US | disclosed |
| WO-2018067786-A1 | SUBSTITUTED 1H-IMIDAZO[4,5-B]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-04-12 | — | — | WO | disclosed |
| US-20180072720-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12384778-B2 | Pyrazolopyridine compounds and uses thereof | PDXK, PCK1, PGK1 | HSD17B10 1056/4885CHRM2 3961/4885CHRM1 4165/4885 |
| US-20200087301-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, PGK1 | HSD17B10 1056/4885CHRM2 3961/4885CHRM1 4165/4885 |
| US-11795166-B2 | Pyrazolopyridine compounds and uses thereof | PDXK, PCK1, PGK1 | HSD17B10 1056/4885CHRM2 3961/4885CHRM1 4165/4885 |
| US-20180072720-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, PGK1 | HSD17B10 1056/4885CHRM2 3961/4885CHRM1 4165/4885 |
| US-20230000833-A1 | SUBSTITUTED 1H-IMIDAZO[4,5-b]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN2C | HSD17B10 2952/4885CHRM2 526/4885CHRM1 378/4885 |
| US-10435405-B2 | Pyrazolopyridine compounds and uses thereof | PDXK, PCK1, PGK1 | HSD17B10 1056/4885CHRM2 3961/4885CHRM1 4165/4885 |
| US-11759455-B2 | Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GLUN2B receptor modulators | GRIN2B, GRIN2A, GRIN2C | HSD17B10 2952/4885CHRM2 526/4885CHRM1 378/4885 |
| US-20190106419-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, PGK1 | HSD17B10 1056/4885CHRM2 3961/4885CHRM1 4165/4885 |
| US-10617676-B2 | Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GluN2B receptor modulators | GRIN2B, GRIN2A, GRIN2C | HSD17B10 2952/4885CHRM2 526/4885CHRM1 378/4885 |
| US-10266530-B2 | Pyrazolopyridine compounds and uses thereof | PDXK, PCK1, PGK1 | HSD17B10 1056/4885CHRM2 3961/4885CHRM1 4165/4885 |
| US-20180125826-A1 | SUBSTITUTED 1H-IMIDAZO[4,5-b]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN2C | HSD17B10 2952/4885CHRM2 526/4885CHRM1 378/4885 |
| US-20240287059-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, PGK1 | HSD17B10 1056/4885CHRM2 3961/4885CHRM1 4165/4885 |
| US-20230338341-A1 | SUBSTITUTED 1H-IMIDAZO[4,5-b]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN2C | HSD17B10 2952/4885CHRM2 526/4885CHRM1 378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.